Randomized Controlled Trial for Wheat Oral Immunotherapy
Conditions: Allergy;Food; Wheat Allergy; Children Interventions: Other: Wheat-containing food Sponsors: Chinese University of Hong Kong Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023. AbbVie, the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
" neoBREASTIM " : Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Conditions: Triple Negative Breast Neoplasms Interventions: Combination Product: Atezolizumab + RP1 Sponsors: Institut Curie; Replimune Inc.; Roche Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
Conditions: Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy Interventions: Drug: Palbociclib; Drug: Rivaroxaban; Genetic: SNP Sponsors: Lebanese University; Haykel Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer; Neoadjuvant Therapy; Radiotherapy; Immunotherapy Interventions: Drug: Toripalimab; Radiation: Conventional segmental radiotherapy; Other: opreation Sponsors: Northern Jiangsu Province People ' s Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte ™ Immunotherapy Platform
NATICK& QUINCY, Mass., Oct. 2, 2023 /PRNewswire/ -- Avenge Bio, Inc. ( " Avenge " or the " Company " ), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Neoplasms, Head and Neck Interventions: Drug: Dostarlimab; Drug: Belrestotug; Drug: GSK6097608 Sponsors: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
Conditions: Advanced Soft Tissue Sarcoma Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Conditions: Squamous Cell Carcinoma of the Oropharynx Interventions: Procedure: Tumor Biopsy Sponsors: Fondation H ôpital Saint-Joseph Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Sublingual Immunotherapy Compared to Intralymphatic Immunotherapy With Concomitant Vitamin D, a Randomised Placebo Controlled Study
Conditions: Allergic Rhinitis Due to Grass Pollen Interventions: Drug: SLIT Grazax ALK Nordic 75 000 SQ-T; Drug: ILIT + Vitamin D; Drug: ILIT + placebo Sponsors: Lars Olaf Cardell Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Conditions: Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Camrelizumab; Lenvatinib Interventions: Procedure: bTAE-HAIC; Drug: Lenvatinib; Drug: Camrelizumab Sponsors: Zhou Qunfang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS ‑001 in Relapsed or Refractory Advanced Solid Tumors
IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies
HOUSTON, TX, September 28, 2023– ImmunoGenesis, a clinical-stage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Adult Solid Tumor Interventions: Drug: Nivolumab; Drug: Visugromab (CTL-002); Drug: Placebo Sponsor: CatalYm GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Durvalumab; Other: Genetic Testing; Procedure: Mammography; Drug: Paclitaxel; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Adult Solid Tumor Interventions: Drug: Nivolumab; Drug: Visugromab (CTL-002); Drug: Placebo Sponsors: CatalYm GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
